Dominic Anthony Hovsepian, MD
Neurology · Los Altos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 6
- 3 carriers
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 757662 · El Camino Health · Mills-Peninsula Medical Center · Sequoia Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
6 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hovsepian’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
6 of 6 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A141089 · Current
Licensed to practise in California · since 2016 · expires 2028-03-31 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$84,781
Medicare paid this office $84,781 for 256 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 117 | $21,859 | $133 |
| New patient visit (45+ min) | 135 | $21,513 | $159 |
| Measurement of brain wave activity (eeg), awake and drowsy | 19 | $12,065 | $464 |
| Long return visit (40+ min) | 56 | $11,972 | $181 |
| New patient visit (60+ min) | 43 | $8,930 | $208 |
See all 9 services
| Return visit (30+ min) | 117 | $21,859 | $133 |
| New patient visit (45+ min) | 135 | $21,513 | $159 |
| Measurement of brain wave activity (eeg), awake and drowsy | 19 | $12,065 | $464 |
| Long return visit (40+ min) | 56 | $11,972 | $181 |
| New patient visit (60+ min) | 43 | $8,930 | $208 |
| Short return visit (20+ min) | 41 | $3,993 | $95 |
| New patient visit (30+ min) | 15 | $1,265 | $84 |
| Short return visit | 12 | $723 | $60 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $576 | $32 |
Who their Medicare patients are
256 Original Medicare patients in 2024. Average age 77 · Women 51% · Also on Medicaid 7% · Health risk score 0.98. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 61% · Coronary heart disease 23% · Diabetes 19% · Dementia 18% · Chronic kidney disease 17% · Cancer 16% · Depression 16% · Atrial fibrillation 15% · Stroke 14% · Heart failure 11% · COPD 6%.
The office billed $262,208, Medicare allowed $108,033 and paid $84,781; for 531 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 256 | 531 | 77 | 0.98 | $262,208 | $84,781 |
| 2023 | 680 | 1,131 | 75 | 1.56 | $490,352 | $107,659 |
| 2022 | 737 | 2,537 | 75 | 1.32 | $632,883 | $139,899 |
| 2021 | 648 | 1,503 | 75 | 1.24 | $664,208 | $152,429 |
| 2020 | 195 | 429 | 74 | 1.23 | $175,173 | $46,750 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 268 | $42,796 | $107 |
| New patient visit (45+ min) | 94 | $14,047 | $149 |
| Short return visit (20+ min) | 123 | $10,686 | $76 |
| Measurement of brain wave activity (eeg), awake and asleep | 163 | $9,088 | $55 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 35 | $7,616 | $155 |
| Long return visit (40+ min) | 23 | $4,171 | $154 |
| Testing of autonomic (sympathetic) nervous system function | 31 | $3,732 | $120 |
| New patient visit (60+ min) | 16 | $2,692 | $168 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 39 | $2,467 | $63 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 24 | $2,413 | $97 |
| Exam of neurobehavioral status, first hour | 23 | $1,966 | $85 |
| Measurement of brain wave activity (eeg), awake and asleep | 38 | $1,604 | $41 |
| Measurement of brain wave activity (eeg), awake and drowsy | 27 | $1,158 | $43 |
2022: 12 services
| Return visit (30+ min) | 292 | $54,125 | $114 |
| Short return visit (20+ min) | 192 | $21,650 | $77 |
| New patient visit (45+ min) | 140 | $20,074 | $143 |
| Measurement of brain wave activity (eeg), awake and asleep | 258 | $13,674 | $52 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 24 | $4,420 | $158 |
| Testing of autonomic (sympathetic) nervous system function | 37 | $4,189 | $113 |
| Measurement of brain wave activity (eeg), 61-84 hours with health care professional review and report | 14 | $3,325 | $238 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 21 | $2,361 | $103 |
| Exam of neurobehavioral status, first hour | 28 | $2,231 | $80 |
| Long return visit (40+ min) | 11 | $2,225 | $171 |
| New patient visit (30+ min) | 22 | $1,988 | $90 |
| Measurement of brain wave activity (eeg), awake and asleep | 31 | $1,374 | $44 |
2021: 13 services
| Return visit (30+ min) | 245 | $44,927 | $119 |
| New patient visit (45+ min) | 224 | $33,618 | $150 |
| Short return visit (20+ min) | 208 | $28,596 | $86 |
| Measurement of brain wave activity (eeg), awake and asleep | 254 | $13,582 | $53 |
| Exam of neurobehavioral status, first hour | 65 | $5,723 | $88 |
| Testing of autonomic (sympathetic) nervous system function | 37 | $5,008 | $135 |
| New patient visit (30+ min) | 37 | $3,900 | $105 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 12 | $2,895 | $161 |
| Measurement of brain wave activity (eeg), 61-84 hours with health care professional review and report | 11 | $2,524 | $229 |
| New patient visit (60+ min) | 11 | $2,087 | $190 |
| Measurement of brain wave activity (eeg), awake and asleep | 46 | $1,996 | $43 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 17 | $1,777 | $105 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 19 | $1,303 | $69 |
2020: 7 services
| Return visit (30+ min) | 111 | $16,116 | $104 |
| New patient visit (45+ min) | 58 | $8,784 | $151 |
| New patient visit (60+ min) | 27 | $5,047 | $187 |
| Measurement of brain wave activity (eeg), awake and asleep | 84 | $4,581 | $55 |
| Exam of neurobehavioral status, first hour | 30 | $2,745 | $92 |
| Long return visit (40+ min) | 19 | $2,683 | $141 |
| Short return visit (20+ min) | 19 | $1,465 | $73 |
Drugs they prescribed that Part D paid
$79,833
Pharmacies billed $79,833 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
974 generic and fewer than 11 brand-name prescriptions · $79,833 in drug cost · 23 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 90 | $2,302 | $26 |
| Carbamazepine Er | 12 | $1,987 | $166 |
| Memantine | 80 | $1,799 | $22 |
| Oxcarbazepine | 18 | $1,538 | $85 |
| Levetiracetam | 54 | $1,536 | $28 |
See all 22 drugs
| Gabapentin | 90 | $2,302 | $26 |
| Carbamazepine Er | 12 | $1,987 | $166 |
| Memantine | 80 | $1,799 | $22 |
| Oxcarbazepine | 18 | $1,538 | $85 |
| Levetiracetam | 54 | $1,536 | $28 |
| Carbidopa-Levodopa | 64 | $1,499 | $23 |
| Donepezil | 107 | $1,220 | $11 |
| Divalproex | 13 | $1,032 | $79 |
| Lacosamide | 12 | $816 | $68 |
| Propranolol | 11 | $799 | $73 |
| Baclofen | 21 | $702 | $33 |
| Lamotrigine | 25 | $664 | $27 |
| Levetiracetam Er | 15 | $449 | $30 |
| Escitalopram | 31 | $449 | $14 |
| Citalopram Hbr | 17 | $447 | $26 |
| Atorvastatin | 48 | $435 | $9 |
| Nortriptyline | 12 | $314 | $26 |
| Rosuvastatin | 27 | $299 | $11 |
| Clopidogrel | 34 | $274 | $8 |
| Quetiapine | 13 | $239 | $18 |
| Trazodone | 20 | $56 | $3 |
| Sertraline | 19 | $28 | $1 |
Year by year
| 2024 | 995 | 283 | None | None | $79,833 |
| 2023 | 2,201 | 340 | None | 6% | $504,997 |
| 2022 | 2,325 | 376 | None | None | $575,476 |
| 2021 | 1,899 | 325 | None | 11% | $447,899 |
| 2020 | 378 | 118 | None | None | $93,288 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Glatiramer Acetate | None | 23 | $85,888 | $3,734 |
| Gamunex-C | Immune globulin | 15 | $72,982 | $4,865 |
| Nuedexta | None | 20 | $38,397 | $1,920 |
| Lacosamide | None | 57 | $13,229 | $232 |
| Ubrelvy | None | 11 | $12,017 | $1,092 |
| Carbamazepine Er | None | 26 | $7,533 | $290 |
| Pregabalin | None | 137 | $7,248 | $53 |
| Gabapentin | None | 326 | $6,716 | $21 |
| Rivastigmine | None | 38 | $6,166 | $162 |
| Memantine | None | 107 | $5,983 | $56 |
| Levetiracetam | None | 119 | $5,982 | $50 |
| Oxcarbazepine | None | 50 | $5,264 | $105 |
| Memantine Hcl Er | None | 24 | $5,233 | $218 |
| Donepezil | None | 151 | $4,621 | $31 |
| Duloxetine | None | 52 | $3,175 | $61 |
| Pyridostigmine | None | 12 | $2,815 | $235 |
| Baclofen | None | 59 | $2,085 | $35 |
| Levetiracetam Er | None | 31 | $1,837 | $59 |
| Lamotrigine | None | 63 | $1,822 | $29 |
| Divalproex | None | 35 | $1,688 | $48 |
| Topiramate | None | 31 | $1,101 | $36 |
| Atorvastatin | None | 66 | $1,066 | $16 |
| Pramipexole Dihydrochloride | None | 17 | $1,050 | $62 |
| Escitalopram | None | 54 | $974 | $18 |
| Mirtazapine | None | 11 | $733 | $67 |
| Clopidogrel | None | 43 | $719 | $17 |
| Quetiapine | None | 27 | $560 | $21 |
| Nortriptyline | None | 36 | $552 | $15 |
| Valproic Acid | None | 13 | $492 | $38 |
| Rosuvastatin | None | 17 | $466 | $27 |
| Rizatriptan | None | 20 | $446 | $22 |
| Amitriptyline | None | 24 | $418 | $17 |
| Trazodone | None | 33 | $410 | $12 |
| Cyclobenzaprine | None | 31 | $373 | $12 |
| Clonazepam | None | 15 | $278 | $19 |
| Primidone | None | 13 | $274 | $21 |
| Phenobarbital | None | 13 | $211 | $16 |
| Sertraline | None | 19 | $128 | $7 |
| Meclizine | None | 17 | $111 | $7 |
| Meloxicam | None | 12 | $29 | $2 |
| Diazepam | None | 14 | $14 | $1 |
2022: 42 drugs
| Glatiramer Acetate | 25 | $103,533 | $4,141 |
| Vimpat | 44 | $74,765 | $1,699 |
| Nuedexta | 18 | $46,701 | $2,595 |
| Xcopri | 20 | $31,312 | $1,566 |
| Ubrelvy | 12 | $12,885 | $1,074 |
| Lacosamide | 36 | $8,062 | $224 |
| Carbamazepine Er | 32 | $6,508 | $203 |
| Gabapentin | 377 | $6,438 | $17 |
| Trokendi Xr | 13 | $6,309 | $485 |
| Eliquis | 11 | $5,972 | $543 |
| Levetiracetam | 135 | $5,876 | $44 |
| Donepezil | 184 | $5,811 | $32 |
| Rivastigmine | 43 | $5,754 | $134 |
| Pregabalin | 147 | $5,473 | $37 |
| Duloxetine | 55 | $4,644 | $84 |
| Rivastigmine | 15 | $4,443 | $296 |
| Memantine | 83 | $4,279 | $52 |
| Oxcarbazepine | 42 | $4,112 | $98 |
| Divalproex | 33 | $2,338 | $71 |
| Pyridostigmine | 25 | $2,297 | $92 |
| Quetiapine | 25 | $2,261 | $90 |
| Levetiracetam Er | 11 | $1,717 | $156 |
| Nortriptyline | 66 | $1,268 | $19 |
| Lamotrigine | 53 | $1,254 | $24 |
| Escitalopram | 39 | $1,237 | $32 |
| Atorvastatin | 86 | $1,131 | $13 |
| Clopidogrel | 45 | $792 | $18 |
| Topiramate | 33 | $778 | $24 |
| Baclofen | 40 | $744 | $19 |
| Rosuvastatin | 27 | $694 | $26 |
| Carbidopa-Levodopa | 17 | $611 | $36 |
| Primidone | 17 | $402 | $24 |
| Cyclobenzaprine | 33 | $345 | $10 |
| Zonisamide | 12 | $331 | $28 |
| Sertraline | 27 | $280 | $10 |
| Pramipexole Dihydrochloride | 12 | $272 | $23 |
| Tizanidine | 11 | $253 | $23 |
| Pantoprazole | 12 | $208 | $17 |
| Venlafaxine Hcl Er | 12 | $206 | $17 |
| Clonazepam | 22 | $188 | $9 |
| Trazodone | 33 | $173 | $5 |
| Meloxicam | 11 | $47 | $4 |
2021: 38 drugs
| Glatiramer Acetate | 26 | $104,772 | $4,030 |
| Vimpat | 86 | $104,595 | $1,216 |
| Nuedexta | 21 | $44,322 | $2,111 |
| Gabapentin | 324 | $7,297 | $23 |
| Levetiracetam | 135 | $5,761 | $43 |
| Eliquis | 11 | $5,424 | $493 |
| Pregabalin | 106 | $5,333 | $50 |
| Rivastigmine | 33 | $4,151 | $126 |
| Carbamazepine Er | 25 | $3,935 | $157 |
| Oxcarbazepine | 41 | $3,706 | $90 |
| Rivastigmine | 12 | $3,556 | $296 |
| Donepezil | 168 | $3,415 | $20 |
| Divalproex Sodium Er | 12 | $1,635 | $136 |
| Memantine | 37 | $1,601 | $43 |
| Phenobarbital | 22 | $1,365 | $62 |
| Lamotrigine | 58 | $1,304 | $22 |
| Divalproex | 31 | $1,219 | $39 |
| Duloxetine | 23 | $1,193 | $52 |
| Atorvastatin | 57 | $1,118 | $20 |
| Baclofen | 29 | $1,114 | $38 |
| Nortriptyline | 52 | $1,094 | $21 |
| Levetiracetam Er | 14 | $1,074 | $77 |
| Primidone | 26 | $615 | $24 |
| Rosuvastatin | 22 | $563 | $26 |
| Zonisamide | 27 | $495 | $18 |
| Quetiapine | 24 | $486 | $20 |
| Clopidogrel | 26 | $486 | $19 |
| Carbidopa-Levodopa | 11 | $478 | $43 |
| Escitalopram | 27 | $420 | $16 |
| Cyclobenzaprine | 52 | $313 | $6 |
| Clonazepam | 22 | $307 | $14 |
| Phenytoin Sodium Extended | 12 | $301 | $25 |
| Topiramate | 20 | $208 | $10 |
| Sertraline | 17 | $200 | $12 |
| Venlafaxine Hcl Er | 12 | $181 | $15 |
| Methylprednisolone | 11 | $82 | $7 |
| Trazodone | 11 | $38 | $3 |
| Diazepam | 17 | $19 | $1 |
2020: 10 drugs
| Vimpat | 25 | $29,773 | $1,191 |
| Levetiracetam | 33 | $1,084 | $33 |
| Gabapentin | 57 | $883 | $15 |
| Lamotrigine | 27 | $612 | $23 |
| Pregabalin | 12 | $546 | $46 |
| Oxcarbazepine | 11 | $416 | $38 |
| Topiramate | 11 | $404 | $37 |
| Donepezil | 18 | $289 | $16 |
| Zonisamide | 11 | $222 | $20 |
| Atorvastatin | 13 | $160 | $12 |
Money from drug and device companies
$1,119 in 2025
| 2025 | 12 | 53 | None | $1,119 |
| 2024 | 19 | 42 | None | $1,111 |
| 2023 | 27 | 114 | None | $2,452 |
| 2022 | 30 | 193 | $8,313 | $12,415 |
| 2021 | 32 | 186 | $5,748 | $9,518 |
| 2020 | 18 | 53 | $4,825 | $5,919 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Botox | $442 | 20 payments
|
| SK Life Science | None | $194 | 13 payments
|
| Neurocrine BioSciences | Ingrezza | $160 | 5 payments
|
| Pfizer | Nurtec Odt | $80 | 4 payments
|
| Biogen | Vumerity | $55 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $46 | 2 payments
|
See all 53 published payments
| Abbvie | Meals · 2025-12-18 | Botox | $17 |
| Pfizer | Meals · 2025-12-03 | Nurtec Odt | $22 |
| SK Life Science | Meals · 2025-12-03 | None | $13 |
| Abbvie | Meals · 2025-11-18 | Qulipta | $11 |
| Novartis Pharmaceuticals | Meals · 2025-11-13 | Kesimpta | $14 |
| Novartis Pharmaceuticals | Meals · 2025-10-28 | Kesimpta | $14 |
| Ucb | Meals · 2025-10-28 | Rystiggo | $15 |
| Abbvie | Meals · 2025-10-24 | Botox | $28 |
| Abbvie | Meals · 2025-10-22 | Qulipta | $11 |
| Genentech USA | Meals · 2025-10-21 | Ocrevus Zunovo | $19 |
| SK Life Science | Meals · 2025-10-08 | None | $22 |
| Abbvie | Meals · 2025-10-02 | Ubrelvy | $21 |
| SK Life Science | Meals · 2025-09-16 | None | $14 |
| Abbvie | Meals · 2025-09-09 | Creon | $7 |
| SK Life Science | Meals · 2025-09-03 | None | $12 |
| Neurocrine BioSciences | Meals · 2025-08-27 | Ingrezza | $36 |
| Lundbeck | Meals · 2025-08-21 | Rexulti | $35 |
| SK Life Science | Meals · 2025-08-19 | None | $13 |
| Pfizer | Meals · 2025-08-07 | Nurtec Odt | $15 |
| Abbvie | Meals · 2025-08-06 | Botox | $30 |
| Neurocrine BioSciences | Meals · 2025-07-30 | Ingrezza | $40 |
| SK Life Science | Meals · 2025-07-22 | None | $31 |
| SK Life Science | Meals · 2025-07-22 | None | $6 |
| Neurocrine BioSciences | Meals · 2025-07-16 | Ingrezza | $13 |
| Biogen | Meals · 2025-07-10 | Vumerity | $28 |
| SK Life Science | Meals · 2025-07-08 | None | $1 |
| SK Life Science | Meals · 2025-07-08 | None | $12 |
| SK Life Science | Meals · 2025-06-11 | None | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-05-27 | Austedo Xr | $20 |
| SK Life Science | Meals · 2025-05-27 | None | $11 |
| Neurelis | Meals · 2025-05-21 | Valtoco | $25 |
| Abbvie | Meals · 2025-05-10 | Qulipta | $30 |
| Amneal Pharmaceuticals | Meals · 2025-05-06 | Rytary | $28 |
| Pfizer | Meals · 2025-04-30 | Nurtec Odt | $26 |
| Neurocrine BioSciences | Meals · 2025-04-30 | Ingrezza | $35 |
| Abbvie | Meals · 2025-04-28 | Botox | $11 |
| Abbvie | Meals · 2025-04-26 | Ubrelvy | $35 |
| SK Life Science | Meals · 2025-04-16 | None | $12 |
| Abbvie | Meals · 2025-04-08 | Ubrelvy | $29 |
| Abbvie | Meals · 2025-04-04 | Botox | $30 |
| Abbvie | Meals · 2025-03-28 | Botox | $32 |
| Abbvie | Meals · 2025-03-27 | Ubrelvy | $7 |
| Abbvie | Meals · 2025-03-25 | Creon | $23 |
| Amneal Pharmaceuticals | Meals · 2025-03-19 | Rytary | $19 |
| Biogen | Meals · 2025-03-18 | Vumerity | $26 |
| Pfizer | Meals · 2025-03-12 | Nurtec Odt | $17 |
| SK Life Science | Meals · 2025-03-12 | None | $32 |
| Abbvie | Meals · 2025-03-04 | Qulipta | $17 |
| Neurocrine BioSciences | Meals · 2025-02-26 | Ingrezza | $36 |
| Abbvie | Meals · 2025-02-20 | Botox | $35 |
| Abbvie | Meals · 2025-02-06 | Qulipta | $30 |
| Abbvie | Meals · 2025-01-24 | Qulipta | $16 |
| Abbvie | Meals · 2025-01-15 | Ubrelvy | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $1,111
| Abbvie | Ubrelvy | $237 | 12 payments
|
| Eisai | Leqembi | $125 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $109 | 3 payments
|
| Ucb | Rystiggo | $96 | 3 payments
|
| Novartis Pharmaceuticals | Kesimpta | $73 | 3 payments
|
| Banner Life Sciences | Bafiertam | $64 | 3 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $49 | 2 payments
|
| Biogen | Tysabri | $49 | 2 payments
|
| Neurelis | Valtoco | $47 | 1 payment
|
| Acorda Therapeutics | Inbrija | $45 | 2 payments
|
| Kyowa Kirin | Nourianz | $34 | 2 payments
|
| Lundbeck | Vyepti | $32 | 1 payment
|
| Sumitomo Pharma America | Aptiom | $24 | 1 payment
|
| MDD US Operations | Gocovri | $24 | 1 payment
|
| Pfizer | Nurtec Odt | $23 | 1 payment
|
| Amgen | Uplizna | $23 | 1 payment
|
| Amneal Pharmaceuticals | Unithroid | $22 | 1 payment
|
| SK Life Science | None | $22 | 1 payment
|
| Averitas Pharma | Qutenza | $15 | 1 payment
|
2023: $2,452
| Teva Pharmaceuticals USA | Austedo | $288 | 10 payments
|
| Jazz Pharmaceuticals | Epidiolex | $250 | 8 payments
|
| Sumitomo Pharma America | Aptiom | $233 | 11 payments
|
| Abbvie | Duopa | $220 | 12 payments
|
| SK Life Science | None | $184 | 7 payments
|
| Celgene | Zeposia | $175 | 17 payments
|
| Impel Pharmaceuticals | Trudhesa | $157 | 10 payments
|
| Biogen | Tysabri | $115 | 5 payments
|
| Neurocrine Biosciences | Ingrezza | $107 | 4 payments
|
| Ucb | Briviact | $71 | 2 payments
|
| Pfizer | Paxlovid | $67 | 3 payments
|
| Neurelis | Valtoco | $67 | 2 payments
|
| Lilly USA | Emgality | $64 | 4 payments
|
| Amneal Pharmaceuticals | Rytary | $51 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $49 | 2 payments
|
| Amgen | Aimovig | $48 | 2 payments
|
| Argenx US | Vyvgart | $48 | 2 payments
|
| Acorda Therapeutics | Inbrija | $46 | 2 payments
|
| Averitas Pharma | Qutenza | $30 | 1 payment
|
| Banner Life Sciences | Bafiertam | $27 | 1 payment
|
| Neuropace | Rns Neurostimulator Kit | $26 | 1 payment
|
| Genentech USA | Ocrevus | $24 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $24 | 1 payment
|
| MDD US Operations | None | $22 | 1 payment
|
| Janssen Pharmaceuticals | Ponvory | $22 | 1 payment
|
| Lundbeck | Vyepti | $20 | 1 payment
|
| Supernus Pharmaceuticals | Oxtellar Xr | $17 | 1 payment
|
2022: $12,415
| SK Life Science | Xcopri | $8,913 | 19 payments
|
| Teva Pharmaceuticals USA | Austedo | $371 | 14 payments
|
| Sunovion Pharmaceuticals | Aptiom | $273 | 14 payments
|
| Abbvie | Qulipta | $263 | 13 payments
|
| Jazz Pharmaceuticals | Epidiolex | $247 | 13 payments
|
| Ucb | Briviact | $246 | 8 payments
|
| Celgene | Zeposia | $224 | 12 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $212 | 24 payments
|
| Janssen Pharmaceuticals | Ponvory | $184 | 8 payments
|
| Lilly USA | Emgality | $163 | 9 payments
|
| Neurocrine Biosciences | Ingrezza | $158 | 6 payments
|
| Biogen | Tysabri | $146 | 8 payments
|
| Alexion Pharmaceuticals | Ultomiris | $140 | 7 payments
|
| GRT US Holding | Qutenza | $122 | 4 payments
|
| Avanir Pharmaceuticals | Nuedexta | $104 | 5 payments
|
| Ironshore Pharmaceuticals | Jornay Pm | $91 | 4 payments
|
| Acorda Therapeutics | Inbrija | $89 | 4 payments
|
| Banner Life Sciences | Bafiertam | $77 | 4 payments
|
| GE HealthCare | None | $65 | 1 payment
|
| Lundbeck | Vyepti | $46 | 2 payments
|
| Exeltis USA | Purified Cortrophin Gel | $44 | 2 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $38 | 2 payments
|
| Avion Pharmaceuticals | Dhivy | $37 | 2 payments
|
| MDD US Operations | None | $27 | 1 payment
|
| Boston Scientific | General - Dbs | $26 | 1 payment
|
| Nevro | Omnia | $24 | 1 payment
|
| Allergan | Botox | $23 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $20 | 1 payment
|
| Neurelis | Valtoco | $20 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $20 | 1 payment
|
2021: $9,518
| SK Life Science | Xcopri | $6,214 | 18 payments
|
| Teva Pharmaceuticals USA | Ajovy | $581 | 19 payments
|
| Ucb | Briviact | $338 | 16 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $336 | 33 payments
|
| AbbVie | Ubrelvy | $234 | 15 payments
|
| Greenwich Biosciences | Epidiolex | $193 | 9 payments
|
| Avanir Pharmaceuticals | Nuedexta | $184 | 9 payments
|
| Neurocrine Biosciences | Ingrezza | $169 | 9 payments
|
| Biogen | Tysabri | $134 | 6 payments
|
| Alexion Pharmaceuticals | Soliris | $121 | 7 payments
|
| Lilly USA | Emgality | $107 | 5 payments
|
| Horizon Therapeutics plc | Uplizna | $101 | 3 payments
|
| Adamas Pharmaceuticals | Gocovri | $85 | 4 payments
|
| Mallinckrodt Hospital Products | Acthar | $76 | 3 payments
|
| Upsher-Smith Laboratories | Tosymra | $57 | 3 payments
|
| Amgen | Aimovig | $54 | 2 payments
|
| Celgene | Zeposia | $51 | 3 payments
|
| Neurelis | Valtoco | $48 | 2 payments
|
| Acorda Therapeutics | Inbrija | $48 | 1 payment
|
| Sunovion Pharmaceuticals | Lonhala Magnair | $47 | 2 payments
|
| Lundbeck | Vyepti | $46 | 2 payments
|
| Boston Scientific | Vercise | $45 | 2 payments
|
| Janssen Pharmaceuticals | None | $44 | 2 payments
|
| Supernus Pharmaceuticals | Qelbree | $37 | 2 payments
|
| Medtronic | Percept | $33 | 1 payment
|
| Kyowa Kirin | Nourianz | $26 | 2 payments
|
| Arbor Pharmaceuticals | Horizant | $22 | 1 payment
|
| Genentech USA | Ocrevus | $20 | 1 payment
|
| Ge Healthcare | None | $19 | 1 payment
|
| Merz Pharmaceuticals | Xeomin | $18 | 1 payment
|
| Xeris Pharmaceuticals | Keveyis | $16 | 1 payment
|
| ACADIA Pharmaceuticals | Nuplazid | $12 | 1 payment
|
2020: $5,919
| SK Life Science | Cenobamate | $4,964 | 8 payments
|
| Teva Pharmaceuticals USA | Ajovy | $128 | 6 payments
|
| Avanir Pharmaceuticals | Nuedexta | $103 | 5 payments
|
| Neurocrine Biosciences | Ingrezza | $102 | 4 payments
|
| Alexion Pharmaceuticals | Soliris | $97 | 5 payments
|
| Greenwich Biosciences | Epidiolex | $79 | 3 payments
|
| Ucb | Briviact | $74 | 3 payments
|
| Allergan | Ubrelvy | $73 | 3 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $70 | 4 payments
|
| Adamas Pharmaceuticals | Gocovri | $39 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $35 | 2 payments
|
| Lilly USA | Emgality | $32 | 2 payments
|
| US WorldMeds | Xadago | $29 | 1 payment
|
| Kyowa Kirin | Nourianz | $24 | 1 payment
|
| Amgen | Aimovig | $23 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $19 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Zeposia | $15 | 1 payment
|
| Arbor Pharmaceuticals | Horizant | $12 | 1 payment
|
Professional record
- NPI
- 1154749588
- Licence
- CA A141089, WI 1467California A141089: Current · expires 2028-03-31
- Trained
- Js Weill Medical College, Cornell University, 2014
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 2084E0001X (2084E0001X); Federal specialty code 2084N0600X (2084N0600X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-04-02
- NPI last updated
- 2024-09-26
- NPI record certified
- 2024-09-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 16130 Juan Hernandez Dr Ste 110, Morgan Hill, CA, 95037 · 855 N Westhaven Dr, Oshkosh, WI, 54904